- Home
- CSTL vs HAFC Comparison
CSTL vs HAFC Comparison
Compare CSTL & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- HAFC
- Stock Information
- Founded
- CSTL 2007
- HAFC 1982
- Country
- CSTL United States
- HAFC United States
- Employees
- CSTL N/A
- HAFC 597
- Industry
- CSTL Medical Specialities
- HAFC Major Banks
- Sector
- CSTL Health Care
- HAFC Finance
- Exchange
- CSTL Nasdaq
- HAFC Nasdaq
- Market Cap
- CSTL 697.9M
- HAFC 748.3M
- IPO Year
- CSTL 2019
- HAFC 1996
- Fundamental
- Price
- CSTL $21.62
- HAFC $24.88
- Analyst Decision
- CSTL Strong Buy
- HAFC Buy
- Analyst Count
- CSTL 6
- HAFC 6
- Target Price
- CSTL $37.67
- HAFC $26.00
- AVG Volume (30 Days)
- CSTL 423.4K
- HAFC 144.4K
- Earning Date
- CSTL 11-03-2025
- HAFC 10-21-2025
- Dividend Yield
- CSTL N/A
- HAFC 4.35%
- EPS Growth
- CSTL N/A
- HAFC N/A
- EPS
- CSTL N/A
- HAFC 2.16
- Revenue
- CSTL $346,269,000.00
- HAFC $233,739,000.00
- Revenue This Year
- CSTL N/A
- HAFC $17.13
- Revenue Next Year
- CSTL N/A
- HAFC $7.95
- P/E Ratio
- CSTL N/A
- HAFC $11.50
- Revenue Growth
- CSTL 20.40
- HAFC N/A
- 52 Week Low
- CSTL $14.59
- HAFC $17.93
- 52 Week High
- CSTL $35.84
- HAFC $27.59
- Technical
- Relative Strength Index (RSI)
- CSTL 50.19
- HAFC 53.83
- Support Level
- CSTL $22.54
- HAFC $24.47
- Resistance Level
- CSTL $24.74
- HAFC $25.27
- Average True Range (ATR)
- CSTL 1.14
- HAFC 0.50
- MACD
- CSTL -0.28
- HAFC -0.03
- Stochastic Oscillator
- CSTL 28.93
- HAFC 33.61
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About HAFC Hanmi Financial Corporation
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.